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Abstract
Background: Dengue is endemic in Cambodia (pop. estimates 14.4 million), a country with poor health and
economic indicators. Disease burden estimates help decision makers in setting priorities. Using recent estimates of
dengue incidence in Cambodia, we estimated the cost of dengue and its burden using disability adjusted life years
(DALYs).
Methods: Recent population-based cohort data were used to calculate direct and productive costs, and DALYs.
Health seeking behaviors were taken into account in cost estimates. Specific age group incidence estimates were
used in DALYs calculation.
Results: The mean cost per dengue case varied from US$36 - $75 over 2006-2008 respectively, resulting in an
overall annual cost from US$3,327,284 in 2008 to US$14,429,513 during a large epidemic in 2007. Patients sustain
the highest share of costs by paying an average of 78% of total costs and 63% of direct medical costs. DALY rates
per 100,000 individuals ranged from 24.3 to 100.6 in 2007-2008 with 80% on average due to premature mortality.
Conclusion: Our analysis confirmed the high societal and individual family burden of dengue. Total costs
represented between 0.03 and 0.17% of Gross Domestic Product. Health seeking behavior has a major impact on
costs. The more accurate estimate used in this study will better allow decision makers to account for dengue costs
particularly among the poor when balancing the benefits of introducing a potentially effective dengue vaccine.
Background
Dengue is the most important mosquito-borne viral dis-
ease worldwide. It is often endemic across tropical and
subtropical areas [1]. Most forms of the disease are self-
limited and vary from undifferentiated fever to classic
and painful dengue fever (DF); however, on rare occur-
rence - particularly among children - complications
occur in the forms of dengue hemorrhagic fever (DHF)
or dengue shock syndrome (DSS) [1]. About 3.6 billion
are at-risk of infection causing 500 million infections
globally each year. Over nine million cases of DF and
18,000 deaths may occur annually [2].
In the context of endemicity, dengue is highly visible
in the community, eliciting fear for dengue complica-
tions among mothers particularly during the dengue
season. Although many developing countries recognize
dengue as a public health concern, little funds are
devoted to control measures. This neglect is likely
related to a number of factors including the absence of
specific treatment, the fact that the vaccine is still in
development stage and that effective vector control
interventions are too expensive for any developing coun-
tries. Above all, compared to other major infectious dis-
eases, dengue ranks low internationally in terms of
disability adjusted life years (DALYs) [3].
Evidence on the societal costs of the disease should
help decision makers in setting priorities especially in
the context of increasing health care costs and potential
development of an effective vaccine. In this respect
some Southeast Asian countries have produced cost of
disease data at the regional and country level. Unfortu-
nately these estimates are based on commonly underre-
ported national surveillance data and failed to account
for non-hospitalized cases or cases presenting with den-
gue related undifferentiated fever that occur in the com-
munity[4-7].
Dengue is endemic - affecting mainly children - in
Cambodia (estimated population 14.4 M). Gross
National Income per capita was US$600 in 2008 http://
web.worldbank.org/. One international study included
Cambodia but with scarce specific data [7]. The World
health Organization (WHO) also estimated the burden
of dengue in Cambodia but level of evidence remained
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estimates of true dengue disease incidence in Cambodia,
this study aimed at estimating the accurate cost of den-
gue and its burden using DALYs. Public expenditure
and also individuals’ out-of-pocket payments were con-
sidered in the analysis. All calculations were performed
for three years (2006, 2007 and 2008) in order to assess
annual variations.
Methods
Estimates of dengue disease incidence
We used dengue incidence and case fatality rates as pro-
vided by Vong et al who conducted an active commu-
nity-based surveillance (ACS) among individuals aged 0-
19 years in Kampong Cham province, Cambodia from
2006 to 2008 [8]. Most of the population (~80%) lives in
the southern and northwestern part of the country,
mainly along the Mekong River. Kampong Cham is a
central province and the most populated of Cambodia.
Conditions of dengue’s transmission are probably quiet
representative of the whole country. A total of 42 vil-
lages were under active fever surveillance comprising a
total study population of 14,354 participants. For groups
of people aged above 20 years, it was assumed that inci-
dences were constant. Since the vast majority of dengue
cases in Cambodia occurred before age 20, assumptions
made for adults appeared reasonable [9].
Cost of illness
In a recent review, Tarricone et al suggested that cost of
illness studies (COI) have to measure as accurately as pos-
sible “the true cost to society” to usefully inform decision
makers. To achieve this goal, COI must include estimates
of costs components and identification of subjects that
bear the costs [10]. We used the methods of Tarriconee t
al to estimate the cost of dengue in Cambodia. Medical
resources include direct treatment costs (hospital costs,
out patients costs, medication) and direct control costs
(vector control programs, prophylaxis) [11]. Productive
costs or indirect costs are costs related to morbidity and
premature mortality [10,11]. We used disease burden inci-
dence data calculated annually for the years 2006-8. To
estimate costs, a bottom-up approach was chosen. We
used dengue incidence and case fatality rates as provided
by Vong et al. Results from the ACS suggested that
health-seeking behavior changed from year to year. While
95% of dengue patients sought care in 2006, only about
50% and less than 40% sought care in 2007 and 2008
respectively [8]. Incidence rates and health seeking beha-
viors are displayed in table 1. For sensitivity analyses, we
held health-seeking behaviors observed in 2006 for 2007
and 2008. We assumed that 2007 large epidemic could
have had an impact on “usual” health care consumption.
The share of private providers (private clinics and
pharmacy) was consistent with the results of the Cambo-
dian Health Survey [12]. Assumptions on costs distribu-
tion among government, families (Out-of-pocket
payments) and other organizations (mainly Non Govern-
mental Organizations (NGOs)) are displayed on Table 2.
Public hospitals and health centers receive public subsidies
that represent 50% of the total expenditure. In addition,
another 20% of total costs are born by Health equity funds
or other mechanisms of health insurance. Out-of-pocket
payments account for the remaining 30%. Private clinics
Table 1 Estimated number of total cases, hospitalized
cases and fatal cases of dengue disease in Cambodia,
incidence by group of age and health seeking behavior
by year
2006 2007 2008
Estimated No. cases 76,933 404,165 121,007
Estimated No. hospitalized cases 31,983 42,704 3,129
Estimated No. fatal cases 153 407 72
Incidence rate
<5 years 16.0 79.2 15.5
5-9 years 15.8 83.7 24.4
10-14 years 8.9 46.2 17.2
15-19 years 1.1 15.2 6.8
>20 years 0.5* 1.5* 1.0*
Health seeking behavior
% who seek care 93 50 37
% public hospital 42 11 3
% private clinic 48 31 28
% health center 2 4 1
% pharmacy 1 5 5
* Expert estimates
Table 2 Unit costs and their distribution
Unit
cost
($US)
Distribution
(%)
Reference
Public User
fees
Other
Direct costs
Direct medical
costs
Public hospital 67 50 30 20 (13-15)
Private clinic 20 100
Health center 33 50 30 20
Pharmacy 5 100
Direct control costs
Larviciding
campaign
500,000 100 (32)
Productive costs
Morbidity 8 100 World
Bank
Mortality 600* 100
*With an annual discount rate of 3%
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Page 2 of 6and pharmacies are fully financed by user fees. Costs fig-
u r e sw e r ed e r i v e df r o ms p e c i f i cs t u d i e sc a r r i e do u to n
Dengue and access to heath care in Cambodia [13-15]. It
was assumed that only one provider delivered health care
although qualitative studies suggest that several health ser-
vices could be sought in some cases [16]. To estimate pro-
ductive costs, a Human Capital Approach (HCA) was
chosen in absence of sound data of the work market in
Cambodia. The World Bank estimated average annual
income of US$600. For each dengue fever episode, an
average of 5 workdays lost was taken, which was consis-
tent with previous studies [17]. It was assumed that this
loss was equal for adults and children since at least one
parent has to forgo his/her activity to care his/her sick
child. In prevalence-based studies, lost expected earnings
caused by premature mortality are assigned to the year of
death [10]. Thus, future losses due to premature mortality
were estimated using life expectancy at age of death with a
starting age of work set at 15 years. A discount rate of 3%
per year was applied in the baseline case and a flat rate
was used for sensitivity analyses.
Burden of disease
DALYs were calculated using Murray’s formula [18] but
also taking into account recent remarks aiming at
improving comparability and transferability of results
[19]. Therefore, local life expectancy was used instead of
standard life expectancy. Thus, DALYs are estimated by
summing years of life lost (YLLs) and years of life lived
with disability (YLDs).
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[20]. Other factors were calculated for 17 groups of age
in 5 year increments (<5 years, 5-9 years and so on until
>80 years). Specific incidence rate of dengue, hospitali-
zation and mortality were used for the first four groups
of age (from <5 to 15-19 years) as provided by Vong et
al [8]. As for previous similar studies carried out in
other countries, a disability weight of 0.81 [4,21,22] and
a duration of disability of 5 days were chosen [17].
Results
Cost of illness
Overall annual dengue costs ranged from US$3,327,284
in 2008 up to US$14,429,513 in 2007 with 2006 showing
comparable amounts to 2008 (Table 3). In absence of a
discount rate applied to future losses due to premature
mortality, total costs doubled. On average the cost per
dengue case was US$75 in 2006 and dropped to US$36
in 2007 and US$27 in 2008. Direct medical cost per
case was $38 in 2006, $15 in 2007 and US$8 in 2008.
When considering cases that sought care in both private
and public sectors, these numbers rose to US$41 in
2006, US$29 in 2007 and US$21 in 2008 per case.
Patients and their families support the highest share of
costs with 65%, 80% and 80% of the total cost for 2006,
2007 and 2008 respectively (Fig. 1). When considering
only direct medical costs, out-of-pocket payments repre-
sented 48%, 60% and 82% of the total for 2006, 2007
and 2008 respectively (Fig. 2). A sensitivity analysis was
performed estimating costs in 2007 and 2008 with
health seeking behaviors of 2006. Thus, costs in 2007
would be multiplied by 1.7 and costs of 2008 by 2.1.
Burden of disease
Estimated DALY rates per 100,000 inhabitants ranged
from 24.3 in 2008 to 116.6 in 2007 with 2006 in
between at 40.0 (Table 4). The share due to premature
mortality (Years of life lost/total DALYs) was 91%, 83%
and 70% for 2006, 2007 and 2008 respectively.
Discussion
On costs
Our analyses confirmed the high societal burden of den-
gue in Cambodia whose total costs represented between
0.03 and 0.17% of Cambodia’s Gross Domestic Product.
Table 3 Costs by year ($US)
2006 2007 2008
Total costs 5,771,079 14,429,513 3,327,284
Direct costs 3,437,570 6,432,840 1,463,189
Medical costs 2,937,570 5,932,840 963,189
Public hospitals 2,132,224 2,846,950 208,633
Private clinics 743,397 2,470,746 688,489
Health centers 57,628 508,384 34,772
Pharmacies 4,322 106,761 31,295
Control costs 500,000 500,000 500,000
Productive costs 2,333,509 7,996,673 1,864,095
Morbidity 632,325 3,321,906 994,579
Mortality (3% discount
rate)
1,701,183 4,674,767 869,516
(Mortality (no discount)) (4,592,640) (12,354,240) (2,197,920)
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Cambodia’sc o s to fi l l n e s sd u et od e n g u ef e v e r .T h e s e
costs calculations were based upon robust estimates
provided by the ACS of a large population. Unlike pre-
vious estimates, proportions of both hospitalized and
ambulatory cases were accounted for [7]. Moreover, the
study provided a longitudinal perspective of the burden
of dengue through estimates from three years with dif-
fering epidemiological patterns. Indeed, the incidence
data encompassed a regular seasonal epidemic year
(2006), a large scale epidemic year (2007) and Year 2008
- a year following a major epidemic. This situation has
been observed to be associated with a year of milder
clinical presentation and lower incidence of dengue
fever [23].
Nevertheless, these numbers still probably represent
an underestimation of the real costs caused by endemic
dengue. Mothers are well aware of the risks of potential
severity during the dengue season. There is a local name
for dengue “krun chheam” which translates into “hemor-
rhagic fever” in Khmer language. As such, during the
rainy season fearing hemorrhagic dengue, it is thought
that more mothers would seek hospital admission when
their children present with febrile illnesses than that
they would during the low dengue season. This phe-
nomenon is likely to saturate hospitals capacities and to
lower global health care quality because of an over-
whelmed staff coping with commonly ill-equipped facil-
ities. As defined by health economists, opportunity costs
would occur when treatments for patients suffering
from other diseases have to be postponed because of the
dengue outbreak [11]. Our results underlined the impor-
tance of health seeking behavior on costs. The sensitivity
analysis showed that changes in heath seeking behavior
in 2007 decreased the medical costs.
COI aim at assessing the economic burden of a given
disease to society. Since introduction of these studies,
their utility in the decision-making process has often
been disputed [10]. Some authors argue that COI merely
identify diseases for which large amount of resources are
already allocated [24]. COI could also fail in identifying
diseases amenable by medical treatment or prevention
[25]. Finally it is difficult to compare COI between
countries of different health care capacity and access of
individuals to adequate health care. Although incidence
of dengue may be among the highest, COI may be pro-
portionately lower compared with more developed
neighboring countries as ill-equipped public and private
hospitals would spend less on symptomatic treatment of
dengue. Indeed, our results indicated that small amounts
were devoted to dengue in Cambodia compared to other
countries with an average cost per case around US$50
[7]. More importantly, despites recent effort by the
Cambodian government to introduce safety nets (insur-
ance) or health equity funds in hospitals, the burden of
this cost is disproportionately born by the patients and
their relatives. In 1997, Cambodia introduced user fees
in order to increase hospital revenue, to limit under-
the-table payments and eventually improve the quality
of care [26,27]. It was thought that the system could
improve financial sustainability and increase heath ser-
vices utilization, as a consequence of higher quality
health services [28]. Hitherto, results from early studies
suggest that overall health care utilization increased fol-
lowing user fees introduction [29]. However, utilization
of the poorer members of the community is not well
documented. In addition nearly half of district hospitals
Figure 2 Proportion of direct medical costs born by families,
government and other stakeholders.
Table 4 Estimated DALYs by year
2006 2007 2008
Estimated total DALYs 5,603 16,330 3,397
Estimated YLLs 5,101 13,583 2,391
Estimated YDLs 502 2,747 1,006
Estimated DALYs rate/10
5inhab. 40.0 116.6 24.3
DALYs: diability adjusted life years
YLLs: years of life lost
YDLs: years of life lived with disability
Figure 1 Proportion of total costs born by families,
government and other stakeholders.
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exemption rates in Cambodia are known to be relatively
low compared to other developing countries [26]. Since
a significant proportion of Cambodians have no access
or cannot afford private health care, many families forgo
healthcare. This would be supported by recent findings
that suggested a lower hospitalization rate for dengue in
Cambodia’s poorest households [14]. For the poorest,
healthcare access or hospital costs remained an insur-
mountable issue [24] because loans and high interest
rates can impoverish them for many years [14].
On DALYs
Our results are consistent with previous studies. Shep-
pard et al. reported a DALY rate of 42 DALYs/100,000
in South East Asia [17] and the WHO estimated 54
DALYs/100,000 caused by dengue in Cambodia in 2004.
However, Sheppard et al. found that 52% of DALYs
were due to premature mortality whereas our results
showed a higher share. Cambodia has a very young
population with about 50% of the population under 20
years. Since duration of disability is very short and the
vast majority of deaths occurred in the 0-20 age group,
our estimate is probably more accurate. Some authors
reproach age weighting in DALYs calculation to give
more value to young adults than to other groups of age
[30]. In the Cambodian demographic context, such
assumption tends to underestimate the true burden of
dengue. Compared to other DALYs estimates provided
by the WHO, the burden of dengue appears similar to
those of Japanese encephalitis (54 DALYs/100,000), tra-
choma (69 DALYs/100,000) or even malaria (143
DALYs/100,000). Regional comparisons suggest a bur-
den equivalent in Thailand (60 DALYs/100,000) and
Laos (93 DALYs/100,000).
Limitations
As mentioned previously, opportunity costs were not
taken into account and are likely to have an important
impact on overall costs. Unfortunately, such data were
not available and further studies are needed to docu-
ment these costs. Incidence rates for groups of age
above 20 years old were based on assumptions. Average
income estimates were based on macroeconomic indica-
tors since accurate data on both salaries and unemploy-
ment rate were not available. Median income is likely to
be inferior to mean income in Cambodia because of a
minority of people with very high incomes. Moreover,
all estimates are subject to inaccuracy since informal
work represents the majority of employment in Cambo-
dia [31]. However, conservative values were taken on
purpose to avoid any overestimation (1 dengue case per
1000 pop. on average).
Implications for health policy
The question is to determine whether COI and DALYs
are helpful in prioritizing resources allocation. At first
glance, burden of dengue could appear as an issue little
importance in Cambodia. DALYs caused by tuberculosis
(1,712 DALYs/100,000) or meningitis (356 DALYs/
100,000) are by far more considerable (WHO 2004 esti-
mates). However, dengue strikes primarily children in
Cambodia, resulting in a lesser impact on DALYs calcu-
lation. Regardless of costs underestimation, the share
born by families clearly gives an indication of the true
burden of dengue for Cambodians. Should a dengue
vaccine be highly cost effective, its introduction in Cam-
bodia would provide great benefits to the population
[17] in terms of reduced incurrence of debt [14].
Conclusions
To conclude, decision makers should take into account
dengue costs particularly among the poor and the psy-
chological stress caused by the disease in the population
(assessed by their willingness to pay) when balancing
the benefits of introducing a potentially effective dengue
vaccine. In Cambodia, dengue is a health issue as much
as an equity concern. This report establishes a methodo-
logical approach that uses more accurate estimates of
dengue disease burden to suggest the importance of
using cost indicators when considering the introduction
of a dengue vaccine in Cambodia. Specific studies
should also document the efficiency of other interven-
tions. Previous studies performed in Cambodia reported
contradictive results [9,32].
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